October 11, 2021

Award-Winning CBD Company with Top 5 Global Player Ambitions | Sweet Earth Holdings (SE)

Midas Letter
Midas Letter
Award-Winning CBD Company with Top 5 Global Player Ambitions | Sweet Earth Holdings (SE)
/

Sweet Earth Holdings Corp (CNSX:SE, OTCMKTS:SEHCF) operates in the cannabidiol (CBD) market with a large focus on the research & development and bioavailability of the chemical founds in cannabis. The company already has CBD distribution across Canada, the US, South America, Europe and Asia. The company is now looking to expand across those geographies to become a top 5 global player

“If you do not aspire to be a top 5 player in the world, you never will be. You have to have instilled you’re going to be a top 5 player. That doesn’t guarantee that you will be, but you have to dream big. The reason I say we are cash flow neutral is that when money comes in, we use that for expansion. If there’s profit leftover that developing the brand, because ultimately we are in this to not be a commodity, we are here to be a high-end product company with a strong brand.” – Sweet Earth CEO Peter Espig

The company aims to differentiate itself using its research & development strategies. Those strategies allow Sweet Earth to add CBD to other company products through collaborative partnerships. As well, the research behind the efficacy and bioavailability of CBD has been the main reason why Sweet Earth has won awards for its products.

Sweet Earth has products across skincare/body care, pet treats, and the old-fashioned smokable pre-rolls.

Watch the full interview for a Sweet Earth Holdings overview and the business behind its top 5 global player ambitions.

Transcript

00:00 – Sweet Earth Holdings Corp (CNSX:SE, OTCMKTS:SEHCF) CEO Peter Espig
00:50 – Sweet Earth Holdings Overview
01:58 – Types of products
03:30 – Company history
05:49 – Sales volume
06:07 – Profitability
07:41 – Top 5 CBD player ambition
10:15 – Financial Report Card

Related Articles

Disclosure

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.